Results 61 to 70 of about 1,577 (196)
Advanced Science, Volume 13, Issue 38, 9 July 2026.Monoclonal antibodies are powerful anticancer therapeutics targeting tumor‐associated antigens. Mass spectrometry enables precise and accurate quantification of mAbs in tumor plasma and healthy organs. Unlike ligand binding assay and radioactivity, mass spectrometry does not suffer from matrix effects and labelling artefacts while facilitating method ...
Domenico Ravazza +9 more
wiley +1 more source
Advances in Cancer Immunotherapy for Solid Tumors
Advanced Science, Volume 13, Issue 35, 24 June 2026.Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz +1 more
wiley +1 more source
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Frontiers in ImmunologyCheckpoint inhibitors targeting the PD-1/PD-L1 axis have revolutionized cancer immunotherapy, yet response rates remain limited. To enhance efficacy, next-generation approaches target T cell-activating cytokines to PD-1 via antibodies.
Xueyuan Zhou +5 more
doaj +1 more source
Radiotherapy in Combination With Cytokine Treatment
Frontiers in Oncology, 2019 Radiotherapy (RT) plays an important role in the management of cancer patients. RT is used in more than 50% of patients during the course of their disease in a curative or palliative setting.
Ondrej Palata +12 more
doaj +1 more source
PLoS ONE, 2021 RationaleMurine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety
Kara Magee +17 more
doaj +1 more source
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
mAbsNovel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities.
Patrizia Murer +9 more
doaj +1 more source
T‐Cell Immunity and Lung Cancer
Respirology, Volume 31, Issue 3, Page 236-249, March 2026.ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley +1 more source
, 2023 Sera of immune mice that were previously cured of their melanoma through a combined radiation and immunocytokine immunotherapy regimen consisting of 12 Gy of external beam radiation and the intratumoral administration of an immunocytokine (anti-GD2 mAb ...
Kaitlin Tetreault (17436324) +18 more
core +1 more source
BMC Cancer, 2020 Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%).
Relinde I. Y. Lieverse +24 more
doaj +1 more source